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Inappropriate drug delivery, secondary toxicities, and persistent chemo- and immunoresistance have tradi-
tionally compromised treatment response in melanoma. Using cellular systems and genetically engineered
mouse models, we show that melanoma cells retain an innate ability to recognize cytosolic double-stranded
RNA (dsRNA) and mount persistent stress response programs able to block tumor growth, even in highly
immunosuppressed backgrounds. The dsRNA mimic polyinosine-polycytidylic acid, coadministered with
polyethyleneimine as carrier, was identified as an unanticipated inducer of autophagy downstream of an
exacerbated endosomal maturation program. A concurrent activity of the dsRNA helicase MDA-5 driving
the proapoptotic protein NOXA resulted in an efficient autodigestion of melanoma cells. These results reveal
tractable links for therapeutic intervention among dsRNA helicases, endo/lysosomes, and apoptotic factors.INTRODUCTION
Melanoma remains a prototype of solid cancers with increasing
incidence and extremely poor prognosis at advanced stages
(Jemal et al., 2008). Considerable effort has been devoted to
the identification of molecular determinants underlying mela-
noma chemo- and immunoresistance (Chin et al., 2006; Gray-
Schopfer et al., 2007). Still, the average survival of patients
with inoperable disseminated metastases is less than 10 months
(Tawbi and Kirkwood, 2007). High throughput histogenetic andfunctional studies have revealed complex mechanisms associ-
ated with treatment failure (Fecher et al., 2008). These range
from increased expression of drug pumps and detoxification
enzymes to a pleiotropic potentiation of key survival pathways
(Fecher et al., 2008; Gray-Schopfer et al., 2007; Soengas and
Lowe, 2003). In addition, apoptotic programs involving the mito-
chondria, the endoplasmic reticulum, or death receptors are
invariably ineffective in vivo (Hersey and Zhang, 2008; Soengas
and Lowe, 2003). Consequently, current anticancer drugs either
do not reach their target(s) in a productive manner or have to beSIGNIFICANCE
Melanoma cells accumulate multiple genetic and epigenetic alterations. Still, they still remain highly sensitive to dsRNA
mimics, shown here for the synthetic molecule pIC. However, the delivery vehicle is critical. PEI, a polycation that favors
endosomal uptake and cytosolic release, was able to shift the mode of action of pIC from a transient innocuous transcrip-
tional program to persistent cycles of fusion events involving a sequential recruitment of Rab7 (a small GTPase), LC3
(autophagosome marker), and lysosomes. A convergent mechanism of cellular stress was found driven by MDA-5 and
involving an efficient NOXA-dependent caspase activation. Selective antitumor activity of [pIC]PEI in vivo further supports
cytosolic dsRNA sensors as viable targets for drug development in melanoma.Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 103
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ities to normal cellular compartments (Tawbi and Kirkwood,
2007). Similarly, melanomas have an inherent ability to bypass
or overcome antitumoral activities of immunomodulators (Ilko-
vitch and Lopez, 2008; Tormo et al., 2006; Verma et al., 2008).
Autophagy, and in particular macroautophagy, which involves
the sequestration of bulk cytosolic components in autophago-
somes for subsequent lysosomal degradation (Xie and Klionsky,
2007), is an understudied process inmelanoma. The clinical rele-
vance of macroautophagy (herein referred to as autophagy for
simplicity) stems from its potential to protect cells against
a variety of intracellular and extracellular stress signals and favor
tumor development (Mathew et al., 2009; Mizushima et al.,
2008). Paradoxically, autophagy has also been associated with
cell death (Kroemer et al., 2009). Thus, excessive or persistent
autophagy can promote cell killing by depletion of key organelles
(e.g., endoplasmic reticulum or mitochondria), rewiring of
survival signals, deregulation of lysosomal enzymes, and/or acti-
vation of caspase-dependent apoptotic programs (Eisenberg-
Lerner et al., 2009; Hoyer-Hansen and Jaattela, 2008; Maiuri
et al., 2007; Xie and Klionsky, 2007). Given these pro- and anti-
apoptotic roles of autophagy, it is unclear whether this program
could be a viable target for drug development (Kroemer and
Levine, 2008; Rubinsztein et al., 2007; Scarlatti et al., 2009).
Autophagy genes can also have pleiotropic roles in the
immune system (Virgin and Levine, 2009). Thus, autophagy
can modulate antigen presentation, inhibit or potentiate inter-
feron responses, and display critical functions in the clearance
of intracellular viral and bacterial pathogens (Levine and Deretic,
2007; Sanjuan and Green, 2008). Typically, these responses are
engaged to protect infected cells or the host (Virgin and Levine,
2009). The precise mechanisms underlying this immune autoph-
agy are not well defined. Membrane-bound pattern recognition
receptors of the Toll-like receptor (TLR) family (particularly
TLR-3, TLR-4, and TLR-7) can favor pathogen sequestration
in autophagosomes (Delgado and Deretic, 2009; Levine and
Deretic, 2007). These TLRs have a restricted expression pattern,
being enriched in cells of the immune system, such as macro-
phages and dendritic cells (Paulos et al., 2007; Wenzel et al.,
2008). Whether melanoma cells have other sensors of viral path-
ogens that can be engaged to induce autophagy and cell death is
unknown.
Here, we have assessed the interplay between autophagy and
apoptosis in the context of tumor cell-selective elimination of
melanoma cells.
RESULTS
Identification of Autophagosome Inducers
in Melanoma Cells
Melanoma cells stably expressing the autophagosome marker
LC3 fused with GFP (Klionsky et al., 2008) were used to screen
for autophagy inducers among commercially available chemo-
therapeutic drugs and immunomodulators. To improve intracel-
lular delivery, cationic carriers, e.g., polyethyleneimine (PEI),
were added to DNA- or RNA-based agents (Bieber et al.,
2002). The initial screen was performed with the SK-Mel-103
cell line. Subsequent validation studies were performed using a
panel of nine human metastatic melanoma cell lines of diverse104 Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc.genetic background (see Table S1 available online), as well as
the well-known B16 mouse melanoma cells. Primary skin mela-
nocytes, keratinocytes, and fibroblasts were included as con-
trols for normal cells. We also tested drug response in mouse
embryonic fibroblasts (MEFs) expressing or deficient for the
autophagy factor Atg5 to provide a genetically controlled model
to assess classical autophagy programs (Salazar et al., 2009).
Multiple drugs were found to promote focal GFP-LC3 fluores-
cence emission without significantly affecting cell viability (A.C.
and M.S.S., unpublished data). Among prodeath agents, the
classical double-stranded RNA (dsRNA) mimic polyinosine-pol-
ycytidylic acid (pIC; Wenzel et al., 2008) complexed with PEI
([pIC]PEI) induced a potent accumulation of GFP-LC3 foci (Fig-
ure 1A). About 50% of cells treated with low doses (0.5–1 mg/
ml) of [pIC]PEI showed GFP-LC3 staining within 2–4 hr. These
results were intriguing as pIC had been linked to autophagy in
immune cells (Delgado et al., 2008), but not in the context of
tumor cell death. Therefore, we focused on the identification of
the cellular machinery that sensed and executed the response
of melanoma cells to [pIC]PEI.
Consistent with autophagy, [pIC]PEI induced electrophoretic
mobility changesof theendogenousLC3,whicharecharacteristic
of lipidation of this protein during autophagy (Figure 1B). [pIC]PEI
also lead to LC3 foci formation in oncogenically transformed
MEFs, an activity that required Atg5 (Figure 1C, upper panels).
In fact, inhibition of LC3 redistribution in Atg5/ cells treated
with [pIC]PEI was as prominent as with rapamycin (Figure 1C),
a classical autophagy inducer (Noda and Ohsumi, 1998).
However, rapamycin and [pIC]PEI were not equivalent. LC3 foci
were transient inmelanoma treatedwith rapamycin, but sustained
with [pIC]PEI (Figure 1D). In addition, rapamycin, but not [pIC]PEI,
inhibited the mTOR pathway as visualized by monitoring the
expression of the phosphorylated S6 kinase (Figure 1E).
Electron microscopy provided independent evidence of auto-
phagosome/autolysosome formation driven by [pIC]PEI. Thus,
large mutivesicular structures (>500 nm diameter; Figure 1Fd)
were found following uptake of [pIC]PEI nanoparticles in mela-
noma cells (Figure 1Fb). This uptake was probably facilitated by
the known activity of PEI to coat geneticmaterial and favor endo-
cytosis (Boussif et al., 1995; Kopatz et al., 2004). Importantly,
neither naked pIC nor PEI alone was able to induce autophago-
some formation (see Figure S1 for representative examples).
Together, these results suggest an mTOR-independent autoph-
agy driven by pIC that requires an appropriate cellular delivery
method.
Selective Melanoma Cell Death after [pIC]PEI -Driven
Autophagy
Notably, in all melanoma cell lines tested in this study, the early
activation of autophagy by [pIC]PEI was invariably followed by
cell death (Figure 1G and Table S1). In contrast, melanocytes
retained their viability and did not display markers of autophagy
(Figures S2A–S2C). Interestingly, although complexed efficiently
with PEI, dsDNA, the immunogenic variant ds-BDNA (Ishii et al.,
2006), or other dsRNA molecules such as pA:U had no obvious
impact on melanoma physiology (Figure S2D and data not
shown). These results are consistent with the known superior
immunomodulatory efficacy of pIC over other dsRNA mimics
(Alexopoulou et al., 2001).
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by [pIC]PEI in Immunocompetent
and Immunosuppressed Mice
A detailed characterization of themechanism of action of [pIC]PEI
would not be meaningful without significant activity in vivo. To
this end, three tumor models were investigated. First, B16 mela-
noma cells were tested following subcutaneous or intravenous
inoculation in immunocompetent mice. In a second setting,
B16 or SK-Mel-103 cells expressing GFP (to allow for noninva-
sive imaging) were used in a surrogate model of lung metastasis
in SCID beige mice (Figures 2A–2D). These animals lack func-
tional B cells, T cells, and NK cells (Croy and Chapeau, 1990),
representing severely immunocompromised backgrounds,
which can be found in melanoma patients. As summarized in
Figures 2A–2D and Figures S3A–S3C, [pIC]PEI showed a consid-
erably stronger antimelanoma activity than naked pIC in all the
models tested, even in the highly immunosuppressed SCID
beige mice, in which pIC had virtually no effect.
The third system analyzed was the Tyr::NRASQ61K; INK4a/
ARF/ mice. These animals develop melanomas with key







C Figure 1. Induction of Autophagy by [pIC]PEI
Results in Melanoma Cell Death
(A) Fluorescence imaging of GFP-LC3 distribution in
SK-Mel-103 melanoma cells treated for 6 hr with 1 mg/ml
[pIC]PEI. Cells treated with PEI as single agent are shown
as reference controls.
(B) Changes in the electrophoretic mobility of the endoge-
nous LC3 in SK-Mel-103 treated for the indicated times
with pIC, [pIC]PEI, or vehicle control (PEI).
(C) Visualization of eGFP-LC3 distribution in wild-type or
Atg5/ MEFs treated for 8 hr with 25 nM Rapamycin
(Rap) or 1 mg/ml [pIC]PEI. pIC-treated cells are included
as controls (upper two rows). Bottom panels show quanti-
fication of the percentage of cells with focal GFP-LC3 at
the indicated times after treatment. Error bars correspond
to SEM of three independent experiments.
(D) Differential response of SK-Mel-103 melanoma cells to
rapamycin and [pIC]PEI determined by visualization of LC3-
GFP fluorescence (upper two rows) and bright-field
microscopy imaging (bottom row). Cells treated with
vehicle were included as controls.
(E) Immunoblots of total cell extracts isolated from SK-
Mel-103 cells treated as indicated and probed with anti-
bodies specific for phospho-S6 or tubulin.
(F) Transmission electron micrographs of melanoma cells
treated with [pIC]PEI. Arrows point to conjugates of pIC
and PEI being endocytosed into the treated cells. Note
the large multivesicular structures at late time points after
[pIC]PEI treatment (Fd).
(G) Murine B16 melanoma cells and the indicated human
melanoma cell lines compared for sensitivity to PEI and
pIC as single agents or in combination. Cell death was esti-
mated by trypan blue exclusion 24 and 48 hr after treat-
ment and presented asmeans ± SEMof three independent
experiments.
Here, again, the antitumor activity of [pIC]PEI
was significantly higher than that of pIC, as
determined by quantification of tumor number,
tumor size, metabolic activity, and histological
analyses (Figures 2E–2G and Figure S3D). Of
note, [pIC]PEI prolongs the progression-free survival (Figure 2E)
at dosing schedules without noticeable secondary toxicities
(see below). Together, these results support an efficient and
tumor cell-selective antitumor activity of [pIC]PEI.
Requirement of ATG5 for [pIC]PEI-Mediated Cell Death
Next, we investigated the molecular basis by which [pIC]PEI
mediates self-killing of melanoma cells. Electronic microscopy
(Figure 3A), real-time fluorescence analyses of GFP-LC3 distri-
bution (Movies S1 and S2), and Nomarski interference contrast
microscopy analyses (Movie S3) indicated that melanoma cell
death invariably followed the activation of classical autophago-
cytic vesicles (see Figure S4 for an example). To confirm that au-
tophagy is a key effector of [pIC]PEI action (and not a byproduct
of cellular stress), knockdown of key autophagy genes (Beclin1
and ATG7) was attempted in various melanoma cells. However,
transient or stable knockdown of these genes induced either
cellular senescence or cell death (A.C. and M.S.S., unpublished
data), as described in other systems (Hoyer-Hansen and Jaat-
tela, 2007; Mathew et al., 2009; Miller et al., 2008). This is consis-
tent with a basal rate of autophagy that can be visualized byCancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 105
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Figure 2. Antimelanoma Activity of [pIC]PEI in
Mice
(A)–(D) are results from SCID Beige mice; (E)–(G) are
results from Tyr::RasQ61K 3 Ink4a/Arf/ mice.
(A) Representative images of lungs of mice 14 days
after intravenous inoculation of B16 melanoma cells
and treatment as indicated and photographed under
visible (Macro) or fluorescent (eGFP) light.
(B) Representation of the mean number of metastases
(±SEM) induced by B16 as indicated in (A). *p < 0.01
between PEI or pIC and [pIC]PEI treatment groups
(n = 5; generalized Mann-Whitney test).
(C) Lung colonization by eGFP-SK-Mel-103 in SCID
beige mice treated with the indicated agents and
assessed by fluorescence imaging and histological
analyses.
(D) Quantification of average number of external lung
nodules (±SEM) in the indicated treatment groups
shown in (C). *p < 0.01 between PEI, pIC, and [pIC]PEI
treatment groups (n = 5; generalized Mann-Whitney
test).
(E) Cohorts of Tyr::RasQ61K x Ink4a/Arf/ mice were
treated topically with a single dose of 200 mg DMBA
at 8 weeks of age. Upon appearance of pigmented
lesions of >1 mm diameter, mice were treated as indi-
cated. Control groups received PEI in 5%glucose. The
fraction of animals with tumors of <1mm diameter
(progression free survival) was represented by Kaplan-
Meier graphs.
(F) Average number of cutaneous melanocytic
neoplasms developing in each of the different treat-
ment groups. Scoring was performed every 5 days
and tumors were grouped by size as indicated.
(G) Representative transverse (left panels) and coronal
sections (right panels) of PET /CT fused images to
assess metabolic activity (18F-FDG incorporation) of
representative examples of mice treated as indicated.
Tumors are encircled with white dashed lines. The
asterisks mark animal hearts.monitoring LC3-GFP dynamics in untreatedmelanoma cells (see
Movie S1). Therefore, to avoid confounding results of testing
drug response in cells whose proliferative capacity and viability
is already severely compromised, [pIC]PEI-driven cell death
was determined in transformed wild-type and Atg5/ MEFs.
Although oncogenically transformed wild-type MEFs were less
sensitive to [pIC]PEI-mediated death than melanoma cells, they
were significantly more sensitive than their Atg5/ counterparts
(Figure 3B). However, it should be noted that Atg5/-trans-
formed MEFs died efficiently at high doses of [pIC]
PEI
(>1 mg/ml;
not shown), perhaps reflecting the dual roles of autophagy in
cell survival and cell death, as in immune cells (Virgin and Levine,
2009).
Requirement of Autophagosome-Lysosome Fusion
in [pIC]PEI -Mediated Cell Death
As indicated above, a defining ultrastructural feature of [pIC]PEI
treatment is the induction of large multivesicular structures
(Figure 1Fd). These vesicles could result from halted autophago-
somes in which lysosomes are either not recruited or dysfunc-
tional (Amaravadi et al., 2007; Ostenfeld et al., 2008). In this
scenario, autophagosomeswould grow in size as a consequence106 Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc.of accumulation of improperly degraded material. Alternatively,
these vesicles could correspond to homotypic fusions among
large endosomes, subsequently recruiting multiple autophago-
somes (to generate hybrid structures, also referred to as amphi-
somes). To assess these possibilities, we transduced melanoma
cells with Cherry-GFP-LC3, which displays dual red-green fluo-
rescence in autophagosomes but loses GFP signal in the acidic
environment of autolysosomes (Tasdemir et al., 2008). We found
that [pIC]PEI, similar to rapamycin, induced autolysosomes in
melanoma cells (see ‘‘red-only’’ LC3 foci in Figure 3C). Support-
ing a lysosomal-dependent mode of action of [pIC]PEI, transient
treatment with the lysosomotropic agent chloroquine protected
melanoma cells against [pIC]PEI-driven cell death (Figure 3D),
without affecting the endosomal uptake of this dsRNA mimic
(as determined by colocalization of FluoRed-labeled [pIC]PEI
with GFP-fused early endosomal protein Rab5; Figure 3E).
Similar inhibitory effects were observed using the broad spec-
trum protease inhibitors E64d and pepstatin A and the vacuolar
ATPase blocker bafilomycin (Figure 3D).
To independently monitor lysosomal activity during [pIC]PEI
treatment, we assayed cells for the ability to process DQ-BSA
(a derivative of BSA whose green fluorescence is quenched
Cancer Cell





Figure 3. [pIC]PEI-Triggered Melanoma Cell Death
Is Driven by Autophagosome-Autolysosome
Formation
(A) Representative bright field (left and middle panels) and
electron microscope (right panel) micrographs of SK-Mel-
103 treated as indicated (30 hr).
(B) Transformed wild-type or Atg5/ MEFs treated with
low dose (0.2 mg/ml) of [pIC]PEI or control. Cell death was
estimated by trypan blue exclusion 48 hr after treatment
and presented as means of three independent experi-
ments.
(C) Confocal fluorescence images of SK-Mel-103 trans-
duced with Cherry-GFP-LC3 to detect autophagosomes
(red and green foci) and autolysosomes (red-only foci) after
treatment with [pIC]PEI, 25 nM Rapamycin (Rap), or solvent
control.
(D) Inhibitory effect of 100 mM bafilomycin (Bafil), 20 mM
chloroquine (Chlor), or 10 mg/ml pepstatin (PEP) on cell
death estimated by trypan blue exclusion 20 hr after treat-
ment with vehicle (white bars) or [pIC]PEI (black bars). Data
are indicated asmeans ± SEM of three independent exper-
iments.
(E) Confocal fluorescence images of SK-Mel-103 cells
stably transfected with eGFP-Rab5 and incubated with
[pIC]PEI labeled with FluoRed. Shown is the internalization
of [pIC]PEI by the melanoma cells in the presence or
absence of chloroquine.
(F) Confocal visualization of lysosomal-dependent proteol-
ysis upon cleavage and release of the fluorescent moiety of
DQ-BSA (green) in control or [pIC]PEI-treated SK-Mel-103.
Chloroquine is included to monitor DQ-BSA emission in
cells with blocked lysosomal activity. Cells were simulta-
neously imaged in the presence of Lysotracker red (LTR-
red) to visualize the lysosomal compartment.
(G) The DQ-BSA-Lysotracker colocalizationwas estimated
in a minimum of 150 cells in two independent experiments,
and it is expressed (as arbitrary fluorescence units) with
respect to control treated cells. Error bars correspond
to SEM.unless cleaved by proteolytic enzymes). As shown in Figures 3F
and 3G, DQ-BSA was efficiently cleaved in the presence of
[pIC]PEI (note that DQ-BSA emission was detected at the lyso-
somes, as indicated by colocalization with Lysotracker red).
Dynamic Endosome Mobilization by [pIC]PEI
Having determined that autophagosomes fuse to active lyso-
somes in response to [pIC]PEI, we assessedwhether these organ-
elles interactedwith or were recruited to endosomes. First, endo-
somal dynamics were assessed in melanoma cells expressing
GFP fused to the late endosomal marker Rab7 (Luzio et al.,
2007). Basal endosome generation and resolution (i.e., progres-
sive reduction in size) was detected in untreated melanoma cells
(Figure S5, right panels; and Movie S4). [pIC]PEI treatment mark-
edly enhanced endosomal activity, inducing a sustained and
multiwave generation of endosomes (Figure S5, left panels;
and Movie S5). These endosomes were found to be filled with
lysosomes, as determined by dual imaging of GFP-Rab7 and
Lysotracker red (Figure 4A). Moreover, time-lapse microscopy
revealed fast kinetics of multiple recruitments of lysosomes to
GFP-Rab7-decorated endosomes (Movie S7; see also a sequen-tial series of fusion events in Figure 4B). Importantly, as shown in
Figure 4A (right panels), endosome-lysosome fusion was signifi-
cantly inhibited if cellsoverexpressedRab7-T22N,aknowndomi-
nant-negative mutant of this protein (Gutierrez et al., 2004). In
total, these results uncovered a dynamic mobilization of endo/
lysosomal compartments in tumor cells treated with [pIC]PEI.
Generation and Resolution of [pIC]PEI-Driven
Amphisome Formation
To determine whether and when autophagosomes are recruited
to endosomes, we imaged melanoma cells simultaneously for
GFP-Rab7, Cherry-LC3, and Lysotracker blue at different time
points after [pIC]PEI addition. As shown in Figure 4C and
Figure S6A, the first event detected was generally the incorpora-
tion of Rab7 to the membrane of preexisting ‘‘empty’’ (early-
endosome) vesicles. LC3 was recruited afterwards usually start-
ing from an initial nucleation event, to ultimately decorate the
entire Rab7-positive vesicles. Lysotracker blue incorporation
into these endosome/autophagosome hybrids (amphisomes)
was found to be the last to occur. At this point, the corresponding
vesicle progressively diminished in size to ultimately becomeCancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 107
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(Figure 4C and Figure S6, see arrows marking the Rab7 > LC3 >
Lysotracker sequence). The presence of Lysotracker did not
interfere with endosomal dynamics, as similar progressive
recruitment and internalization of LC3 to Rab7 endosomes was
found in its absence (Figure 4D).
[pIC]PEI Links Autophagy to Apoptotic Caspases
Notably, the sequential fusion events mentioned above for
a single vesicle were found to involve large numbers of endo-
somes and occur in a persistent manner throughout the entire
cytosol of treated cells (Figure S6). This was independent of
the imaging reagents used (see examples of cells imaged with





Figure 4. Generation and Resolution of Am-
phisomes upon [pIC]PEI Treatment
(A) SK-Mel-103 cells stably transfected with eGFP-
Rab7 wild-type or eGFP-Rab7 T22N were incu-
bated with [pIC]PEI for visualization of Rab7 (green
fluorescence) and Lysotracker red. Microphoto-
graphs were captured by confocal microscopy
10 hr after treatment with [pIC]PEI. Values in insets
correspond to the average area contained in
Rab7-decorated vesicles.
(B) Sequence of confocal microphotographs taken
at the indicated time intervals (in seconds) to illus-
trate the fusion to and incorporation of lysosomes
to Rab7-positive vesicles upon [pIC]PEI treatment.
(C) Real-time triple-imaging fluorescence micros-
copy of GFP-Rab7 wild-type, Cherry-LC3, and
Lysotracker blue (green, red, and blue fluores-
cence, respectively) in SK-Mel-103 cells treated
with [pIC]PEI. Images were taken at the indicated
time intervals (in minutes), 1 hr after treatment initi-
ation. Arrows mark the first sequence in which the
indicated markers appear visible.
(D) Incorporation of LC3 to the surface of Rab7
endosomal vesicles prior to internalization and
subsequent degradation. These endosome/LC3
hybrid structures (amphisomes) were visualized
by fluorescence real-time microscopy of SK-Mel-
103 cells expressing eGFP-Rab7 wild-type and
Cherry-LC3.
FigureS6B). Still, we foundaconsiderable
delay from the starting point of endosome
mobilization (2–5 hr), until final cellular
collapse (24–48 hr). Thus, we hypothe-
sized that cell demise required an addi-
tional, later event. Interestingly, cleaved
regulatory and effector caspases (casp-
8, 9, 7, and 3) were detected 15–20 hr
after [pIC]PEI treatment (Figure S7A).
Accordingly, caspase inhibitors (zVAD-
fmk, and to a lesser extent DEVD-CHO)
reduced [pIC]PEI-driven cell death (Fig-
ure S7B). Similarly, the sensitivity of
MEFs to [pIC]PEI was significantly reduced
in cells deficient for the apoptotic factors
Bax and Bak (Figure S7C, left panels).
Importantly, neither caspase inactivation
in melanoma cells nor BAX/BAK deficiency in MEFs prevented
the generation of GFP-LC3 foci (Figures S7B and S7C). Therefore,
[pIC]PEI is able to induce an early but persistent autophagy and
a late apoptotic program. This is in contrast to other systems
where caspases are the initiating death signals and autophagy
is induced to favor the clearance of partially degraded cytosolic
components (Kroemer and Levine, 2008).
Differential Gene Expression Induced by Naked
and PEI-Complexed pIC in Melanoma Cells
Next, we investigated the molecular sensor(s) of [pIC]PEI that
might link autophagy to apoptosis in a tumor cell-selective
manner. Using cDNA arrays, we found melanocytes to undergo
minimal changes in gene expression at early or late time points108 Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc.
Cancer Cell






Figure 5. MDA-5 Is a Sensor and Driver of
[pIC]PEI Cytotoxicity in Melanoma Cells
(A) Fold induction of the transcript levels of the
indicated pathogen-associated receptors relative
to nontreated cells. The IFIT-1 gene was used as
a reference for a classical IFN-responsive factor.
(B) Inhibition of TLR-3 expression by transient
transduction of siRNA (left panels) or stable infec-
tionwith lentivirus coding for shTLR3 (right panels).
Cell death was assessed by trypan blue exclusion
after treatment with vehicle (white bars) or [pIC]PEI
(black bars). Insets correspond to mRNA levels
detected by RT-PCR. Data are shown as means ±
SEM of three independent experiments.
(C) MDA-5 induction visualized by immunoblotting
in SK-Mel-28 and SK-Mel-147 treated with PEI,
pIC, or [pIC]PEI. Bortezomib was used as a control
for an effective death inducer. Full-length and
cleaved MDA-5 (MDA-5FL and MDA-5C, respec-
tively) are indicated with arrows. Asterisk corre-
sponds to a nonspecific band (not blocked by
MDA-5 shRNA; not shown).
(D) MDA-5 mRNA levels (left panel) and cell death
(right panels) in SK-Mel-103 infected with the
pLKO lentivirus expressing scrambled or MDA-5
shRNAs and treated as indicated. Data are shown
as means ± SEM of three independent experi-
ments. p < 0.05 between control and shMDA-5
cells in the presence of [pIC]PEI (two-tailed
Student’s t test).
(E) Inhibition of MDA-5 expression by transient
transduction of a second set of control and
MDA-5 siRNAs driven by the psi-vector frame
(see Experimental Procedures). Cell death in
control and [pIC]PEI-treated SK-Mel-103 (24 hr)
was determined by trypan blue exclusion and
plotted as means ± SEM of three independent
experiments. In the [pIC]PEI treatment group, p <
0.05 between control shRNA and shMDA-5-trans-
duced cells (two-tailed Student’s t test).
(F) Confocal visualization of GFP-LC3 in MeWo
melanoma cells infected with adenovirus control
or adenovirus MDA-5. [pIC]PEI was included as a
reference for autophagosome formation. Numbers
represent fraction of cells with eGFP-LC3 foci.
(G) Cell death resulting from adenovirus-driven
expression of MDA-5 in MeWo cells. The viral
concentration (in plate forming units [pfu]) is indi-
cated. Data correspond to means ± SEM of three
independent experiments.after treatment with pIC or [pIC]PEI. In contrast, melanoma cells
responded to both agents with substantial alterations of their
transcriptome (Figure S8A). Interestingly, while pIC induced
expected changes in interferon response genes, this response
was largely transient. In contrast, the effect of [pIC]PEI was sus-
tained and extended to additional transcripts (Figures S8A and
S8B). These results reveal key idiosyncratic differences between
melanocytes and melanoma cells regarding the uptake and
signaling to dsRNA mimics.
Qualitatively Different Activation of MDA-5 by pIC
in the Absence and Presence of PEI
The best known innate programs that control the sensing of long
dsRNA are (1) the Toll-like receptor 3, (2) the melanoma differen-
tiation-associated gene-5 (MDA-5)/interferon induced with heli-case C domain 1 protein (IFIH1), and (3) the dsRNA-activated
protein kinase (PKR, also known as eIF2AK2) (Takeuchi and
Akira, 2008). Of these genes, MDA-5 showed the strongest
and most sustained induction by [pIC]PEI (Figure 5A). Moreover,
knockdown of TLR3 with independent siRNA or shRNA had no
impact on [pIC]PEI-driven cell death (Figure 5B). Therefore, we
focused on MDA-5 for further analyses. Protein immunoblotting
demonstrated a sustained activation of full-length MDA-5 by
[pIC]PEI (Figure 5C). In addition, an apoptosis-associated pro-
cessing of MDA-5 (Barral et al., 2007; Kovacsovics et al., 2002)
was found preferentially (and in a more sustained manner) in
[pIC]PEI-treated cells (Figure 5C). Of note, this induction and pro-
cessing of MDA-5 was not simply a consequence of activated
apoptotic programs. Treatment with bortezomib, a proteasome
inhibitor that engages intrinsic apoptotic pathways in melanomaCancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 109
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MDA-5 levels or processing (Figure 5C).
Downregulation of MDA-5 expression by siRNA (Figure 5D) or
shRNA (Figure 5E) reduced [pIC]PEI-driven cell death by 50%–
60%, providing evidence for a critical role of MDA-5 as sensor
and effector of this dsRNA mimic. Interestingly, although MDA-
5 needs interaction with dsRNA for full activation (Takeuchi and
Akira, 2008), ectopic expression of this protein is sufficient to
promote cell death in a subset of melanoma cells (e.g., MeWo
[Kang et al., 2004, 2002]). In these cells, MDA-5 was also found
to engage focal aggregation of LC3 (Figure 5F) prior to cell killing
(Figure 5G and data not shown). These results uncover a proau-
tophagy role of MDA-5. However, although MDA-5 may favor
autophagy, it is unlikely that this is the sole contribution of this
protein to [pIC]PEI-mediated cell death. Thus, MDA5-shRNA or
Mda-5/ MEFs could still engage autophagosome formation
after sustained treatment with [pIC]PEI (data not shown).
MDA-5-Driven NOXA-Dependent Cell Death
A main known role of endogenous MDA-5 is to elicit IFN
responses to blunt viral infection (Takeuchi and Akira, 2008).
IFN-a was secreted in [pIC]PEI-treated melanoma cells (data
not shown). However, IFN-a was a poor inducer of melanoma
cell death, even at doses 100 times higher than those secreted
by [pIC]PEI -treated cells (Figure S8C).
cDNAmicroarraydatageneratedabovewasanalyzed to identify
mediators of [pIC]PEI/MDA-5-driven melanoma cell death. Among
known proapoptotic factors, a strong and sustained upregulation
(up to 16-fold) of NOXA mRNA and protein levels was found
(Figures 6A–6D). Moreover, [pIC]PEI-mediated death induction
was reduced by 50%–60% when the NOXA level was reduced
using a shRNA (Figures 6E and 6F). Importantly, [pIC]PEI-driven
NOXA induction was significantly abrogated by MDA-5 shRNA
(Figure 6G). Therefore, these results uncover functional links
between dsRNA sensors and the apoptosis program via NOXA.
Other chemotherapeutic agents such as the proteasome
inhibitor bortezomib can also upregulate NOXA and kill mela-
noma cells deficient for Apaf-1 or other apoptotic modulators
(Fernandez et al., 2005; Qin et al., 2005). However, a main disad-
vantage of bortezomib is that it concomitantly induces various
antiapoptotic factors, including MCL-1, a NOXA antagonist
(Qin et al., 2006; Wolter et al., 2007). In contrast, no compensa-
tory accumulation ofMCL-1 protein was found in the response to








B Figure 6. [pIC]PEI Engages Apoptosis via NOXA
Independently of the Status of p53 or without
Inducing Compensatory MCL-1 Activation
(A) Heat map of log2 ratio values of the indicated genes
after pIC or [pIC]PEI treatment of SK-Mel-103 and calcu-
lated with respect to control (PEI)-incubated cells.
(B) Immunoblots of total cell extracts isolated from
SK-Mel-103 treated for 24 and 48 hr with pIC, [pIC]PEI, or
Bortezomib for the relative levels of NOXA, p53, and anti-
apoptotic Bcl-2 and Bcl-xL proteins.
(C) SK-Mel-28 and SK-Mel-147 (expressing p53 L145A
and p53 wild-type, respectively) were treated with PEI,
pIC, [pIC]PEI, or 25 nM Bortezomib. Shown are the relative
levels of NOXA and MCL-1 protein at different time points
after treatment.
(D) Quantification of the levels of Mcl-1 and NOXA in
SK-Mel-28 after each treatment and represented with
respect to control untreated cells.
(E) NOXA protein expression in melanoma SK-Mel-103
treated for 24 hr with pIC or [pIC]PEI 2 days after infection
with a lentiviral vector expressing inactive shRNA (sh
Ctrl) or shRNA for NOXA.
(F) Death rates (±SEM) of control and NOXA shRNA trans-
duced SK-Mel-103 melanoma cells and incubated with
pIC or [pIC]PEI for 24 hr.
(G) Inhibitory effect of MDA-5 downregulation on NOXA
induction by [pIC]PEI determined in SK-Mel transduced
with control or MDA5 shRNAs. Data is represented as
means ± SEM of four independent experiments. Levels
of NOXA were quantified by densitometry of the corre-
sponding immunoblots and plotted with respect to
untreated controls.
(H) Immunoblots of total cell extracts isolated from SK-
Mel-103 treated for 24 hr with vehicle or [pIC]PEI in the
presence or absence of chloroquine and probed for the
detection of MDA-5 (full-length and cleaved forms) and
NOXA.110 Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc.
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C
B Figure 7. Defining the Mode of Action of
[pIC]PEI In Vivo
(A) Response of oncogenically transformed wild-
type (+/+) or Mda-5/ (/) MEFs, measured as
time-dependent changes in tumor size (±SEM)
upon treatment with naked pIC (V) or [pIC]PEI.
Shown are p values for comparative analyses
between the indicated treatment groups (n = 10,
generalized Mann-Whitney test). Inset bar graphs
corresponds to death rates (±SEM; n = 3) of the
indicated cell populations 24 hr after treatment in
culture with 1 mg/ml [pIC]PEI.
(B) SK-Mel-103 GFP-LC3 melanoma cells
implanted subcutaneously into SCID beige mice
were left to grow to 6–8 mm diameter and then
treated with PEI or [pIC]PEI. Paraffin-embedded
sections were stained for LC3 or NOXA antibodies.
For LC3, high magnification photographs are also
included to show the formation of foci character-
istic of autophagosomes.
(C) Model summarizing main results of this study.
A transient activation of IFN and other antiviral
stress response factors by naked pIC (1) can be
shifted into a sustained stress program when this
dsRNA mimic is delivered to cells with PEI (2).
PEI packs pIC into nanoparticles and favors both
its endosomal uptake and delivery to the cytosol
for subsequent activation of the helicase MDA-5
(3). In addition to favor endosomal swelling, PEI
has been described to favor endosome-endo-
some fusion. Within 2–3 hr after incubation with
[pIC]PEI melanoma cells undergo massive ultra-
structural changes in the endosomal compartment
(4). These changes involve a sustained and cyclic
Rab7 > LC3 > Lysotracker sequence of fusion
events, revealing an active generation and resolution of endosome-autophagosome-lysosome hybrids (5). AlthoughMDA-5 can facilitate autophagosome forma-
tion, a main function of this protein described here is the induction of the proapoptotic factor NOXA (6). NOXA is per se a poor apoptotic inducer, but can lower the
threshold for caspase processing. Sustained lysosomal-dependent degradative process together with the activation of apoptotic caspases can ultimately
converge in efficient tumor cell death (7). Importantly, we demonstrate a potent anti-melanoma activity of [pIC]PEI in various animal models, at concentrations
with no obvious toxicity to normal cellular compartments.Importantly, the induction of MDA-5 and NOXA by [pIC]PEI was
found to occur even when lysosome activity was blocked by
chloroquine or by cathepsin inhibitors (Figure 6H and Figure S7D
and data not shown). Thus, NOXA can be activated indepen-
dently of the autophagy program. From a therapeutic perspec-
tive, it was interesting to note that cDNA arrays failed to identify
changes in NOXA expression in melanocytes (data not shown).
Similarly, MDA-5 and NOXA were not upregulated in skin fibro-
blasts (Figure S8D), which also showed increased resistance to
[pIC]PEI in culture (Figure S8E) and no obvious signs of toxicity
in biopsies from treated animals (Figure S8F; note also lack of
toxicity to other organs).
[pIC]PEI-Mediated Therapeutic Effects In Vivo: MDA-5
Requirement, LC3 Foci Formation, and NOXA Induction
Next, we investigated the dependency on MDA-5 and the dual
activation of autophagosome and apoptotic markers identified
above by [pIC]PEI in vivo. Available antibodies against MDA-5
cannot distinguish full length from processed forms of this
protein. In the absence of current Mda-5-deficient mouse mela-
noma models, we decided to take advantage of homozygous
knockout MEFs for the Mda-5 gene. As shown in Figure 7A,
transformed Mda-5/ MEFs were significantly more resistantto [pIC]PEI than their wild-type counterparts, both in tissue
culture systems and when grown as xenografts in mice.
Selective antibodies for LC3 and NOXA were used to visualize
autophagosome formation and activation of NOXA by [pIC]PEI in
human melanoma xenografts. Although sporadic stainings for
LC3 or NOXA were detected in vehicle-treated SK-Mel-103
xenografts, the total number of positive cells and the corre-
sponding signal intensity of NOXA or LC3 per individual cell
were noticeably stronger in the [pIC]PEI-treated specimens
(Figure 7B). The animal model used (SCID beige) is highly immu-
nodeficient. Therefore, these results serve as the proof-of-prin-
ciple for the ability of [pIC]PEI to bypass the requirement for
immune effectors and drive tumor cell death by a coordinated
autophagy/apoptosis mechanism.
DISCUSSION
Melanomas accumulate a plethora of genetic and epigenetic
alterations that contribute to the limited efficacy of current anti-
cancer treatments (Chin et al., 2006; Soengas and Lowe,
2003). However, here we have shown that melanoma cells retain
the ability to sense and respond to mimetics of viral dsRNA and
that this feature can be exploited therapeutically. Specifically,Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc. 111
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sensors of dsRNA, endo/lysosomal compartments, and tumor
cell death.
Given the ability of melanoma cells to deactivate death
programs (Gray-Schopfer et al., 2007), it is intriguing that they
remain sensitive to lysosomal-dependent autodegradative
mechanisms. This is particularly relevant because autophagy
has been abundantly linked to cytoprotection in innate and
acquired immune responses (Levine and Deretic, 2007; Sanjuan
and Green, 2008; Virgin and Levine, 2009). Activation of auto-
phagosomes by TLR3 has also been reported for naked dsRNA
in macrophages, but in this case, for protection of the host at
both the cellular and organismal levels (Delgado et al., 2008).
In the melanoma cells studied here, however, TLR3 was found
dispensable for [pIC]PEI-driven autophagy or apoptotic induc-
tion, perhaps reflecting inherent differences in TLR3 expression
between professional immune cells and melanomas.
An intriguing feature of the response of melanoma cells to
[pIC]PEI was a considerable time lag from the detection of the first
series of endosome-autophagosome-lysosome fusions (within
an hour of treatment) to the final cellular collapse (24–48 hr). It
is therefore conceivable that autophagy is engaged in response
to [pIC]PEI as an initial mechanism of protection, which is later
shifted into a prodeath program (see model in Figure 7C).
Thus, autophagy could be engaged to resolve an exacerbated
endocytosis driven by pIC complexed to PEI (Boussif et al.,
1995; Kopatz et al., 2004). Endocytic recruitment of autophago-
somes could initially help tumor cells to maintain a ‘‘clean’’
cytosol. Intraendocytic degradation would prevent leakage or
the accumulation of partially degraded autophagocytic struc-
tures, and/or damaged lysosomes, which could be potentially
lethal to cells (Kroemer and Jaattela, 2005). However, the phys-
ical concentration of autophagosomes and lysosomes within
endocytic vesicles may also provide a point of vulnerability of
melanoma cells. Recurrent cycles of endo/lysosome genera-
tion-degradation could lower the threshold for the activation of
death programs (i.e., by depleting ATP and/or key proteins or
organelles required for cell maintenance) as described in other
systems (Eisenberg-Lerner et al., 2009). In fact, amain difference
between [pIC]PEI (which kills melanoma cells) and rapamycin
(innocuous to melanoma cells) is the sustainability of the endoly-
sosome-autophagosome fusion events. An additional defining
feature of [pIC]PEI not shared by rapamycin or by other chemo-
therapeutic agents is the ability to engage a potent wave of proa-
poptotic events driven, at least in part, by the MDA-5 dsRNA
sensor (see Figure 7C).
MDA-5, a helicase now considered as a first line of defense
against viral dsRNA (Kato et al., 2006), was first described as a
melanoma differentiation-associated gene (Kang et al., 2002).
It was noted that MDA-5 had proapoptotic activities when
expressed ectopically at high levels (Kang et al., 2004; Kovac-
sovics et al., 2002). However, even forced expression of MDA-
5 was rather inefficient in tumor cells with hyperactivated RAS/
MEK/ERK pathway (Lin et al., 2006), as is the case of melanomas
(Gray-Schopfer et al., 2007). Therefore, it was unclear how to
drive a sustained activation of the endogenous MDA-5 protein.
Moreover, the identity of death-inducing targets of MDA-5
remains unclear (Takeuchi and Akira, 2008). We showed that
endogenousMDA-5 can in fact be induced to kill melanoma cells112 Cancer Cell 16, 103–114, August 4, 2009 ª2009 Elsevier Inc.(with pIC delivered appropriately to the cytosol). Further, we
uncovered roles of MDA-5 beyond the activation of IFN-driven
immune responses. Specifically, we showed the ability of
MDA-5 to drive autophagosome formation and NOXA activation.
Still, our data also suggest that additional death inducers acti-
vated by [pIC]PEI are likely to act in parallel or in concert with
MDA-5 and NOXA (i.e., depletion of these proteins do not
completely abrogate the antitumoral activity of [pIC]PEI). In this
context, the cDNA arrays performed here indicate that [pIC]PEI
can selectively induce a variety of stress kinases with proauto-
phagic and proapoptotic activity (D.T. and M.S.S., unpublished
data).
From a therapeutic perspective, perhaps one the most unex-
pected findings in this study is the cell-autonomous anti-tumoral
activity of [pIC]PEI. pIC has been used formore than four decades
as a synthetic dsRNA mimic to boost the immune system in an
IFN-dependent manner (Field et al., 1967). Unfortunately, clinical
trials with naked pIC showed poor pIC stability and IFN induction
and no detectable antitumor effect in melanoma (Robinson et al.,
1976). Complexes with low molecular weight poly-L-lysine,
carboxymethylcellulose, liposomes, or PEI have been reported
to favor pIC’s therapeutic activity via IFN-dependent immune
responses (Fujimura et al., 2006; Levine et al., 1979). Our results
show that PEI significantly enhances the ability of pIC to induce
melanoma cells to express classical IFN-a targets. However, we
also show that IFN, per se, does not recapitulate the anti-mela-
noma activity of [pIC]PEI in cultured cells. Moreover, [pIC]PEI
can display an efficient anti-melanoma activity in animals with
defective NK, T, or B cell signaling, a condition common of mela-
noma patients (Kirkwood et al., 2008; Wenzel et al., 2008). In
addition to the xenografts in immunosuppressed and immuno-
deficient mice, our results in two additional in vivo models
(MDA-5-deficient cells and autochthonous cutaneous mela-
nomas generated in the Tyr::NRASQ61K; INK4a/ARF/ mice)
further emphasized the physiological relevance of our data. Alto-
gether, our results provide the proof of principle for dsRNA
sensors as therapeutic targets to overcome the inherent resis-
tance of melanoma cells to current anticancer treatments.
EXPERIMENTAL PROCEDURES
Treatment, Imaging, and Expression Analyses in Cultured Cells
The human and mouse metastatic melanoma cell lines used in this study are
described in the Supplemental Experimental Procedures. Normal human
melanocytes and fibroblasts were isolated from anonymous discarded fore-
skins as previously reported (Wolter et al., 2007), using protocols approved
by the University of Michigan and the Instituto Carlos III-CNIO ethics commit-
tees. Wild-type and Atg5- or Bax/Bak-deficient MEFs have been described
before (Kuma et al., 2004; Lindsten et al., 2000). Oncogenically transformed
derivatives of these cells, expressing HRASG12V and the SV40 large T antigen,
were a kind gift of G. Velasco (Universidad Complutense,Madrid, Spain). Infor-
mation on PEI-complexed pIC, pharmacological inhibitors of apoptosis and
autophagy, and other reagents and techniques used here to assess cell death
and cell viability are described in the Supplemental Experimental Procedures.
Details on transmission electron microscopy, confocal and fluorescence
microscopy, protein immunoblotting, lentiviral mediated RNA interference,
and cDNA microarray expression profiling are also described in the Supple-
mental Experimental Procedures. Full data sets corresponding to the cDNA
arrays reported in this study in melanocytes and SK-Mel-103 cells were
deposited to the Gene Expression Omnibus database (with accession
numbers GSE16337 and GSE14445, respectively).
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All experiments in mouse models were performed in accordance with institu-
tionally approved protocols by the University of Michigan Unit for Laboratory
Animal Medicine Committee and the Instituto Carlos III-CNIO ethics
committee. Generation and treatment of autochthonous melanomas in the
Tyr::N-RasQ61K/; Ink4a/Arf/mice and the analysis of melanoma xenografts
in C57BL/6 and in the immunosuppressed SCID beige mice are summarized
in the Supplemental Experimental Procedures.
Histopathological and Immunohistochemical Analyses
Tumors or tissue sections from the indicated treatment groups were fixed in
10% buffered formalin, embedded in paraffin, and routinely stained with
hematoxylin and eosin. Alternatively, tumors were immunostained with the
NOXA antibody (Calbiochem) and LC3 antibody (Cell Signaling). Slides were
digitalized with Dotslide (Olympus).
Statistical Analyses
Viability data are expressed as means ± SEM and statistical analysis of the
differences was determined by the two-tailed Student’s t test. For statistical
evaluation of tumor growth andmetastasis in vivo, the generalizedMann-Whit-
ney test was used to compare the values of continuous variables between two
groups. p values of < 0.05 were considered significant.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, eight
figures, one table, and seven movies and can be found with this article online
at http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00217-7.
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